УЛГАЙГАН БЕЙТАПТАРДА ЖҮРӨК - КАН ТАМЫР СИСТЕМАСЫНЫН ООРУЛАРЫНЫН АЛДЫН АЛУУ (АДАБИЙ СЕРЕП)
DOI:
https://doi.org/10.54890/1694-8882-2024-5-41Аннотация
Акыркы он жылдыктарда жашоонун узактыгы бир кыйла өстү. Бул сценарийде, жүрөк-кан тамыр тобокелдик факторлору жана жүрөк-кан тамыр оорулары бар улгайган адамдардын жашоо прогнозун жана сапатын жакшыртуу үчүн саламаттыкты сактоо чаралары зарыл. Бирок, клиникалык сыноолорго киргизилген улгайган пациенттердин саны аз, ошондуктан учурдагы клиникалык практикалык көрсөтмөлөр конкреттүү сунуштарды
камтыбайт. Бул документтин максаты ≥ 75 жаштан жогорку же өтө жогору жүрөк-кан тамыр коркунучу бар пациенттерге багытталган профилактикалык сунуштарды карап чыгуу, максаттарга, медициналык дарылоонун варианттарына, ошондой эле көнүгүүлөрдү жана аны кардиохирургиялык реабилитациялык программаларга киргизүүнү камтыйт. Ошондой эле алсыздык, көз карандылык, когнитивдик бузулуу жана тамактануу абалы сыяктуу гериатриялык синдромдор, ошондой эле коштолгон оорулар, алардын маанилүү прогностикалык таасири үчүн бул калкта эмне үчүн каралышы керектигин көрсөтөт. Эң кеңири тараган кошумча ооруларды, анын ичинде улгайган кишилерде көбүнчө диагноз коюлган аз кандуулукту, ошондой эле пациенттердин психикалык абалын баалоо маанилүү, анткени депрессия бул популяцияда кеңири таралган жана когнитивдик бузулуу менен чаташтырылып же бири-бирине дал келиши мүмкүн, ошондой эле татаалдашуулардын күчөшү. жана жүрөк-кан тамыр оорулары жана өлүм.
Ключові слова:
жүрөк-кан тамыр системасы, карылык, алдын алууПосилання
1. INE. National Statistics Institute. INE. 2024. Available from: https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&cid=1254736177004&m enu= ultiDatos&idp=1254735573002.
2. Madhavan MV, Gersh BJ, Alexander KP, Granger CB, Stone GW. Coronary Artery Disease in Patients ≥80 Years of Age. J Am Coll Cardiol. 2018;71(18):2015-2040. https://doi.org/10.1016/j.jacc.2017.12.068
3. Díez-Villanueva P, Arizá-Solé A, Vidán MT, Bonanad C, Formiga F, Sanchis J, et al. Recommendations of the Geriatric Cardiology Section of the Spanish Society of Cardiology for the Assessment of Frailty in Elderly Patients With Heart Disease. Rev Esp Cardiol (Engl Ed). 2019;72(1):63-71. https://doi.org/10.1016/j.rec.2018.06.035
4. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet. 2020;396(10263):1644-1652. https://doi.org/10.1016/S0140-6736(20)32233-9
5. Gencer B, Marston NA, Im K, Cannon C P, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637-1643. https://doi.org/10.1016/S0140-6736(20)32332-1
6. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255. doi: 10.1093/eurheartj/ehz826]. Eur Heart J. 2020;41(1):111-188. https://doi.org/10.1093/ eurheartj/ehz455
7. Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020;41(24):2248-2258. https://doi.org/10.1093/eurheartj/ehz809
8. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593−603. https://doi.org/10.1177/ 2047487319864671
9. Yusuf S., Hawken S., Ounpuu S. Dans, T., Avezum, A., Lanas, F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): casecontrol study. Lancet 2004;364(9438): 937−952. https://doi.org/10.1016/S0140-6736(04)17018-9
10. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control [published correction appears in N Engl J Med. 2017 Dec 21;377(25):2506. https://doi.org/10.1056/NEJMx170008]. N Engl J Med. 2015;373(22):2103-2116. https://doi.org/10.1056/NEJMoa1511939
11. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019 Feb 1;40(5):475. https://doi.org/10.1093/eurheartj/ehy686]. Eur Heart J. 2018;39(33):3021-3104. https://doi.org/10.1093/ eurheartj/ehy339
12. Windle SB, Bata I, Madan M, Abramson BL, Eisenberg MJ. A randomized controlled trial of the efficacy and safety of varenicline for smoking cessation after acute coronary syndrome: design and methods of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome trial. Am Heart J. 2015;170(4):635-640.e1. https://doi.org/ 10.1016/j.ahj.2015.07.010
13. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting with out persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(19):1289-1367. https://doi.org/10.1093/eurheartj/ehaa895
14. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coron- ary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213−260. https://doi.org/10.1093/eurheartj/ehx419
15. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. https://doi.org/10.1056/NEJMoa0706482
16. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. NEngl J Med. 2015;372(19):1791-1800. https://doi.org/10.1056/NEJMoa1500857
17. Sanchis J, Soler M, Núñez J, Ruiz V, Bonanad C, Formiga F, et al. Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome. Eur J Intern Med. 2019;62:48−53. https://doi.org/10.1016/j. ejim.2019.01.018
18. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622-626. https://doi.org/ 10.1111/j.1532-5415.1968.tb02103.x
19. Bureau ML, Liu E, Christiaens L, Pilotto A, Mergy J, Bellarbre F, et al. Using a multidimensional prognostic index (MPI) based on comprehensive geriatric assessment (CGA) to predict mortality in elderly undergoing transcatheter aortic valve im- JOURNAL OF GERIATRIC CARDIOLOGY REVIEW plantation. Int J Cardiol. 2017;236:381-386. https://doi.org/10.1016 /j.ijcard.2017.02.048
20. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14(6):392−397. https://doi.org/10.1016/j.jamda.2013.03.022
21. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 [published correction appears in Age Ageing. 2018 May 1;47(3):489. https://doi.org/10.1093/ageing/afx178]. Age Ageing. 2015;44(2):213-218. https://doi.org/ 10.1093/ageing/afu145
22. Тажибаева У.Ж., Арстанбекова М.А., Мусакеев А.К. Нартаева А.К., Иманалиева Ф.Э., Маматов С.М. Патофизиологические аспекты и лечение дефицита железа у пожилых людей (обзор литературы). Вестник КГМА им И.К. Ахунбаева. 2023;2:65-72. https://doi.org/10.54890/1694-6405_2023_2_65
23. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071−2082. https://doi.org/10.1016/j.jacc.2014 .08.021
24. Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016;67(1):1−12. https://doi.org/10.1016/j.jacc.2015.10.044
25. Vanhees L, De Sutter J, Gelada SN, Doyle F, Prescott E, Cornelissen V, et al. Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the EACPR (Part I). Eur J Prev Cardiol. 2012;19(4):670-686. https://doi.org/10.1177/20474873124 37059
26. Brown TM, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, et al. Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's get with the guidelines program. J Am Coll Cardiol. 2009;54(6):515-521. https://doi.org/10.1016/j.jacc.2009.02.080
##submission.downloads##
Жарыяланганы
Як цитувати
Номер
Розділ
